Fundraising Fox

Biotech Late Stage Investors & VC Firms

652 firms in this list, with a median first check of $1M. 131 of them lead rounds. Generated from verified public data and updated continuously.

Essex Woodlands Healthcare Partners
New YorkGrowth–Late Stage$20M – $80M
18 people
McKesson Ventures
San FranciscoSeed–Late Stage
15 people
Telegraph Hill Partners
San FranciscoGrowth–Late Stage$2M – $8M
18 people
+ND Capital
WoodsideSeed–Late Stage$540K – $5.4M
17 people
AME Cloud Ventures
Palo AltoSeed–Late Stage$1M – $10M
8 people
Invest-NL
AmsterdamPre-Seed–Late Stage
23 people
Apposite Capital
LondonGrowth–Late Stage
22 people
Delos Capital
CambridgeSeed–Late Stage
17 people
Blue Horizon Corporation
ZurichPre-Seed–Late Stage
Oberland Capital
New YorkGrowth–Late Stage$50M – $300M
20 people
Ajax Health
Menlo ParkSeed–Late Stage
26 people
Green Pine Capital Partners
ShenzhenPre-Seed–Late Stage$425K – $150M
2 people
Adjuvant Capital
New YorkSeries A–Late Stage$10M – $25M
19 people
Takeda Ventures
CambridgePre-Seed–Late Stage$1M – $5M
19 people
Avaana Capital
MumbaiSeed–Late Stage
18 people
The March Group
DavisPre-Seed–Late Stage
24 people
MassVentures
WalthamPre-Seed–Late Stage$250K – $500K
10 people
TrueLight Capital
SingaporeSeed–Late Stage
28 people
Blue Ocean Capital Group
ShenzhenLate Stage
23 people
Heal Capital
BerlinPre-Seed–Late Stage$1M – $5M
15 people
Crescent Capital Partners
SydneySeries A–Late Stage$13.2M – $52.8M
24 people
Northstar Ventures
Newcastle upon TynePre-Seed–Late Stage$38.1K – $1.3M
19 people
Debiopharm Innovation Fund
LausannePre-Seed–Late Stage$1M – $5M
18 people
LVX Ventures
BangalorePre-Seed–Late Stage$179K – $10M

Related lists

Data sourced from public filings and firms' own websites — see our methodology.